Amgen-AstraZeneca Combo Boosts Survival in Late-Stage Lung Cancer Trial
AMGN sits 46% above its 52-week low of $269.77 on elevated volume (2.4× avg).
Summary
Amgen's Imdelltra combined with AstraZeneca's Imfinzi significantly improved overall survival in extensive-stage small-cell lung cancer in a late-stage trial, also improving progression-free survival and response rate with no new safety concerns. This is a major positive for Amgen's oncology franchise, which accounts for about 23% of total sales; Imdelltra alone brought in $513 million last year. The result comes after a rough stretch for Amgen, including a 9% share plunge earlier today on Novartis's pelacarsen failure and recent Tavneos regulatory troubles. The trial success could support expanded use of Imdelltra and strengthen Amgen's competitive position in lung cancer. Watch for detailed data presentation at an upcoming medical meeting and potential regulatory submissions.
At the time of this announcement, AMGN was trading at $393.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $212.6B. The 52-week trading range was $269.77 to $447.03. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.